214 related articles for article (PubMed ID: 34342024)
1. Effects and safety evaluation of Wuzhi Capsules combined with tacrolimus for the treatment of kidney transplantation recipients.
Cheng F; Li Q; Wang J; Zeng F; Zhang Y
J Clin Pharm Ther; 2021 Dec; 46(6):1636-1649. PubMed ID: 34342024
[TBL] [Abstract][Full Text] [Related]
2. Effects of Wuzhi Capsules on Blood Concentration of Tacrolimus in Renal Transplant Recipients.
Yan L; Yang ZQ; Shi YY; Ren J; Yang CL; Wan ZL; Bai YJ; Luo LM; Wang LL; Li Y
Ann Transplant; 2019 Nov; 24():594-604. PubMed ID: 31712547
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effects of Wuzhi Capsule on tacrolimus blood concentrations in liver transplant patients with different donor-recipient CYP3A5 genotypes.
Kou K; Sun X; Li M; Li T; Hu Y; Li S; Lv G
J Clin Pharm Ther; 2022 Feb; 47(2):200-210. PubMed ID: 34708436
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients.
Jing Y; Kong Y; Hou X; Liu H; Fu Q; Jiao Z; Peng H; Wei X
J Clin Pharm Ther; 2021 Aug; 46(4):1117-1128. PubMed ID: 33768546
[TBL] [Abstract][Full Text] [Related]
5. Wuzhi Tablet (
Li J; Chen S; Qin X; Fu Q; Bi H; Zhang Y; Wang X; Liu L; Wang C; Huang M
Drug Metab Dispos; 2017 Nov; 45(11):1114-1119. PubMed ID: 28864749
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interactions between tacrolimus and Wuzhi capsule in liver transplant recipients: Genetic polymorphisms affect the drug interaction.
Huang S; Song W; Jiang S; Li Y; Wang M; Yang N; Zhu H
Chem Biol Interact; 2024 Mar; 391():110906. PubMed ID: 38340974
[TBL] [Abstract][Full Text] [Related]
7. Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats.
Wei H; Tao X; Di P; Yang Y; Li J; Qian X; Feng J; Chen W
Drug Metab Dispos; 2013 Jul; 41(7):1398-403. PubMed ID: 23628674
[TBL] [Abstract][Full Text] [Related]
8. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.
Chen P; Li J; Li J; Deng R; Fu Q; Chen J; Huang M; Chen X; Wang C
J Clin Pharm Ther; 2017 Feb; 42(1):93-97. PubMed ID: 27885697
[TBL] [Abstract][Full Text] [Related]
9. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetic study of tacrolimus and
Qu J; Bian R; Liu B; Chen J; Zhai J; Teng F; Guo W; Wei H
Front Pharmacol; 2022; 13():956166. PubMed ID: 36188616
[No Abstract] [Full Text] [Related]
11. Effect of drug combination on tacrolimus target dose in renal transplant patients with different
Zhang SF; Tang BH; Wei AH; Du Y; Guan ZW; Li Y
Xenobiotica; 2022 Mar; 52(3):312-321. PubMed ID: 35395919
[TBL] [Abstract][Full Text] [Related]
12. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
Zhang JJ; Liu SB; Xue L; Ding XL; Zhang H; Miao LY
Int J Clin Pharmacol Ther; 2015 Sep; 53(9):728-36. PubMed ID: 26227094
[TBL] [Abstract][Full Text] [Related]
13. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
[TBL] [Abstract][Full Text] [Related]
14. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
15. Clinical observation on the effect of Wuzhi soft capsule on FK506 concentration in membranous nephropathy patients.
Zhang Z; Lu X; Dong L; Ma J; Fan X
Medicine (Baltimore); 2019 Nov; 98(48):e18150. PubMed ID: 31770256
[TBL] [Abstract][Full Text] [Related]
16. Effect of hepar-protecting Wuzhi capsule on pharmacokinetics and dose-effect character of tacrolimus in healthy volunteers.
Teng F; Wang W; Zhang W; Qu J; Liu B; Chen J; Liu S; Li M; Chen W; Wei H
Biopharm Drug Dispos; 2022 Aug; 43(4):119-129. PubMed ID: 35180322
[TBL] [Abstract][Full Text] [Related]
17. Prediction of tacrolimus and Wuzhi tablet pharmacokinetic interaction magnitude in renal transplant recipients.
Chen P; Dai R; She Y; Fu Q; Huang M; Chen X; Wang C
Clin Transplant; 2022 Dec; 36(12):e14807. PubMed ID: 36057787
[TBL] [Abstract][Full Text] [Related]
18. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
[TBL] [Abstract][Full Text] [Related]
19. Initial dose optimization of tacrolimus for children with systemic lupus erythematosus based on the CYP3A5 polymorphism and coadministration with Wuzhi capsule.
Chen X; Wang D; Xu H; Li Z
J Clin Pharm Ther; 2020 Apr; 45(2):309-317. PubMed ID: 31755126
[TBL] [Abstract][Full Text] [Related]
20. Effect of Wuzhi preparations on tacrolimus in CYP3A5 expressers during the early period after transplantation: A real-life experience from heart transplant recipients.
Zhou Y; Huang X; Liu L; Zeng F; Han Y; Zhang J; Zhou H; Zhang Y
Transpl Immunol; 2023 Feb; 76():101748. PubMed ID: 36423734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
